TY - JOUR
T1 - Improving Rosacea Outcomes in Skin of Color Patients
T2 - A Review on the Nuances in the Treatment and the Use of Cleansers and Moisturizers
AU - Alexis, Andrew F.
AU - Woolery-Lloyd, Heather
AU - Andriessen, Anneke
AU - Desai, Seemal
AU - Han, George
AU - Rodriguez, David
N1 - Publisher Copyright:
© 2022 Journal of Drugs in Dermatology. All rights reserved.
PY - 2022/6
Y1 - 2022/6
N2 - Background: While rosacea is a common inflammatory condition that affects diverse populations, published data in skin of color (SOC) are limited. This review explored nuances in clinical presentation and treatment considerations in SOC patients with rosacea and the role of cleansers and moisturizers in the management of rosacea Do Not in these Copypopulations. Methods: A panel reviewed and discussed aspects of rosacea Penalties in SOC Apply and possible implications for treatment and maintenance. The outcome of these discussions, coupled with the panel's expert opinion and experience was used to define draft statements. After group discussions and an online review process, the panel agreed on the inclusion and wording of five statements. Results: Studies and anecdotal clinical experience suggest that rosacea is more common in SOC populations than previously reported. The clinical presentation of rosacea across diverse skin types includes the spectrum of clinical subtypes observed in other populations; however, clinical features may be less conspicuous in individuals with higher skin phototypes and the index of suspicion may be lower in SOC populations. To avoid underdiagnosis, dermatologists should consider rosacea in the differential diagnosis of any patient presenting with a history of skin sensitivity, central facial erythema, papules, and pustules. The compromised barrier in rosacea contributes to skin sensitivity. Studies including Chinese rosacea patients showed that using a moisturizer and sunscreen negatively correlated with rosacea development. Conclusions: The use of skincare could improve rosacea symptomatology. These products are recommended before and during prescription therapy and as part of a maintenance regimen as adjuncts.
AB - Background: While rosacea is a common inflammatory condition that affects diverse populations, published data in skin of color (SOC) are limited. This review explored nuances in clinical presentation and treatment considerations in SOC patients with rosacea and the role of cleansers and moisturizers in the management of rosacea Do Not in these Copypopulations. Methods: A panel reviewed and discussed aspects of rosacea Penalties in SOC Apply and possible implications for treatment and maintenance. The outcome of these discussions, coupled with the panel's expert opinion and experience was used to define draft statements. After group discussions and an online review process, the panel agreed on the inclusion and wording of five statements. Results: Studies and anecdotal clinical experience suggest that rosacea is more common in SOC populations than previously reported. The clinical presentation of rosacea across diverse skin types includes the spectrum of clinical subtypes observed in other populations; however, clinical features may be less conspicuous in individuals with higher skin phototypes and the index of suspicion may be lower in SOC populations. To avoid underdiagnosis, dermatologists should consider rosacea in the differential diagnosis of any patient presenting with a history of skin sensitivity, central facial erythema, papules, and pustules. The compromised barrier in rosacea contributes to skin sensitivity. Studies including Chinese rosacea patients showed that using a moisturizer and sunscreen negatively correlated with rosacea development. Conclusions: The use of skincare could improve rosacea symptomatology. These products are recommended before and during prescription therapy and as part of a maintenance regimen as adjuncts.
UR - http://www.scopus.com/inward/record.url?scp=85131771496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131771496&partnerID=8YFLogxK
U2 - 10.36849/JDD.6838
DO - 10.36849/JDD.6838
M3 - Article
C2 - 35674765
AN - SCOPUS:85131771496
SN - 1545-9616
VL - 21
SP - 574
EP - 580
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 6
ER -